Recurrence Pattern of Cervical Cancer Based on the Platinum Sensitivity Concept: A Multi-Institutional Study from the FRANCOGYN Group.
advanced cervical cancer
platinum sensitivity
recurrence pattern
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
12 Nov 2020
12 Nov 2020
Historique:
received:
20
09
2020
revised:
01
11
2020
accepted:
09
11
2020
entrez:
17
11
2020
pubmed:
18
11
2020
medline:
18
11
2020
Statut:
epublish
Résumé
The standard of care for patients with advanced cervical cancer (ACC) includes platinum-based chemotherapy. The concept of platinum sensitivity is a major prognostic factor for patients with ovarian cancer. The aim of this study was to validate the applicability of the platinum sensitivity concept to ACC patients, and to estimate its prognostic interest in terms of overall survival (OS) and pattern of recurrence (location, timing). Data of women with histologically proven FIGO 2019 stages IB3-IV ACC, treated between May 2000 and November 2017 with platinum-based regimens, were retrospectively abstracted from 12 institutions from the FRANCOGYN Group. Respective 3-year OSs were 52% (95% CI: 40.8%-66.8%), 21.6% (95% CI: 12.6%-37.2%), and 14.6% (95% CI: 4.2%-50.2%), in case of recurrence <6 months, between 6 and 17 months, and ≥18 months (
Identifiants
pubmed: 33198384
pii: jcm9113646
doi: 10.3390/jcm9113646
pmc: PMC7696862
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Surg Oncol. 2019 Apr;45(4):659-665
pubmed: 30685326
Tumour Biol. 2016 May;37(5):6359-69
pubmed: 26631032
Transl Oncol. 2017 Jun;10(3):378-384
pubmed: 28432899
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S43-103
pubmed: 17161167
Cancer Chemother Pharmacol. 2011 Aug;68(2):337-42
pubmed: 20976599
Int J Gynecol Cancer. 2013 Nov;23(9):1670-4
pubmed: 24172102
Oncology (Williston Park). 1992 Apr;6(4):27-32; discussion 37-8, 43
pubmed: 1533780
J Natl Compr Canc Netw. 2008 Jan;6(1):53-7
pubmed: 18267059
Gynecol Oncol. 2012 May;125(2):307-11
pubmed: 22333993
Surg Oncol. 2019 Sep;30:40-46
pubmed: 31500783
Crit Rev Oncol Hematol. 2014 Feb;89(2):207-16
pubmed: 24071502
Int J Gynaecol Obstet. 2019 Apr;145(1):129-135
pubmed: 30656645
Semin Oncol. 1996 Jun;23(3 Suppl 6):56-64
pubmed: 8677451
J Gynecol Oncol. 2015 Jul;26(3):185-92
pubmed: 26197856
J Clin Oncol. 2007 Jul 10;25(20):2952-65
pubmed: 17617527
Eur J Gynaecol Oncol. 2002;23(2):104-10
pubmed: 12013102
J Biochem Mol Toxicol. 2019 Apr;33(4):e22267
pubmed: 30506648
J Clin Oncol. 2002 Apr 1;20(7):1832-7
pubmed: 11919241
J Natl Compr Canc Netw. 2004 Nov;2(6):631-5
pubmed: 19780305
N Engl J Med. 2014 Feb 20;370(8):734-43
pubmed: 24552320
Cancer Chemother Pharmacol. 2017 Oct;80(4):697-705
pubmed: 28785994
Life Sci. 2015 Dec 15;143:217-24
pubmed: 26585822
Cancer Chemother Pharmacol. 2016 Oct;78(4):785-90
pubmed: 27553435
Bull Cancer. 2017 Dec;104(12):1032-1038
pubmed: 29173977
Cochrane Database Syst Rev. 2012 Oct 17;10:CD006469
pubmed: 23076924
Gynecol Oncol. 1990 Feb;36(2):207-11
pubmed: 2404837
J Clin Oncol. 1991 Mar;9(3):389-93
pubmed: 1999708
Rev Invest Clin. 2020;72(4):231-238
pubmed: 33064705
J Clin Oncol. 2009 Oct 1;27(28):4649-55
pubmed: 19720909